--News Direct--
On the heels of ASCO22, we remain committed to innovating in the oncology space, particularly for cancers with high unmet needs, like platinum-resistant ovarian cancer. Thomas Herzog, M.D. and Craig Hopkinson M.D. share their insights on how our actively recruiting ARTISTRY-7 clinical trial in platinum-resistant ovarian cancer aspires to address these needs: https://bit.ly/3azbAjw
View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com
View source version on newsdirect.com: https://newsdirect.com/news/alkermes-remains-committed-to-oncology-innovation-463188612